JP2021530558A - 近赤外光免疫療法による治療法を試験するための方法 - Google Patents
近赤外光免疫療法による治療法を試験するための方法 Download PDFInfo
- Publication number
- JP2021530558A JP2021530558A JP2021520095A JP2021520095A JP2021530558A JP 2021530558 A JP2021530558 A JP 2021530558A JP 2021520095 A JP2021520095 A JP 2021520095A JP 2021520095 A JP2021520095 A JP 2021520095A JP 2021530558 A JP2021530558 A JP 2021530558A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- apc
- amount
- procedure
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 103
- 238000011282 treatment Methods 0.000 title claims abstract description 68
- 238000012360 testing method Methods 0.000 title claims abstract description 7
- 239000003446 ligand Substances 0.000 claims abstract description 55
- 210000002700 urine Anatomy 0.000 claims abstract description 29
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 28
- 238000004458 analytical method Methods 0.000 claims abstract description 23
- 230000005855 radiation Effects 0.000 claims abstract description 18
- 230000001678 irradiating effect Effects 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 15
- 238000000375 direct analysis in real time Methods 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 238000000132 electrospray ionisation Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 229960002806 daclizumab Drugs 0.000 claims description 4
- 229950010203 nimotuzumab Drugs 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 229960002087 pertuzumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 abstract description 10
- 238000010586 diagram Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000975 dye Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 101710131520 B melanoma antigen 1 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001007 phthalocyanine dye Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102100035565 B melanoma antigen 2 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102100039701 G antigen 2B/2C Human genes 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100039698 G antigen 5 Human genes 0.000 description 1
- 102100039713 G antigen 6 Human genes 0.000 description 1
- -1 GAGE3 Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000874318 Homo sapiens B melanoma antigen 2 Proteins 0.000 description 1
- 101000886151 Homo sapiens G antigen 2A Proteins 0.000 description 1
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
- 101000886135 Homo sapiens G antigen 5 Proteins 0.000 description 1
- 101000886141 Homo sapiens G antigen 6 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102100025081 Melanoma-associated antigen 2 Human genes 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
Claims (16)
- 近赤外光免疫療法による治療法の効率と有効性を試験するための方法であって、
抗体・光増感剤複合体(APC)を患者の体内に注入する手順、
前記患者に放射線を当てることにより、該患者の尿中に排出されるリガンドを前記APCから放出させる手順、
液体クロマトグラフィ質量分析により前記リガンドの存在を検出する手順、及び、
前記液体クロマトグラフィ質量分析の分析結果に基づいて前記患者の尿中に存在する前記リガンドの量を測定及び定量化する手順
を備えることを特徴とする方法。 - 前記患者の体内に残存する前記APCの量を特定するために前記患者の尿中に存在する前記リガンドを測定し、定量化された量に基づいて前記近赤外光免疫療法による治療法の有効性を判定する手順
を更に備えることを特徴とする請求項1に記載の方法。 - 前記APCの抗体がペプチド、小分子及びそれらの組み合わせを含むことを特徴とする請求項1に記載の方法。
- 前記APCの抗体が、セツキシマブ、パニツムマブ、ザルツムマブ、ニモツズマブ、マツズマブ、トラスツズマブ、ペルツズマブ、リツキシマブ、ダクリズマブ、J591、又はその抗原結合性フラグメントであることを特徴とする請求項1に記載の方法。
- 前記APCの光増感剤が、親水基に結合した疎水性色素骨格を含む両親媒性分子であることを特徴とする請求項1に記載の方法。
- 前記APCの光増感剤が疎水性色素を含むことを特徴とする請求項1に記載の方法。
- 前記APCの光増感剤がIRDye(登録商標)700であることを特徴とする請求項1に記載の方法。
- 前記患者に当てられる放射線が近赤外光であることを特徴とする請求項1に記載の方法。
- 前記患者に当てられる放射線が660〜740nmの波長を有することを特徴とする請求項1に記載の方法。
- 放出される前記リガンドがC14H33NO10S3Siフラグメントであることを特徴とする請求項1に記載の方法。
- 前記液体クロマトグラフィ質量分析が、三連四重極質量分析装置、プローブエレクトロスプレイイオン化質量分析装置(PESI−MS)、DART(Direct Analysis in Real Time)質量分析装置(DART−MS)又は大気圧固体試料分析プローブ質量分析装置(ASAP−MS)を用いるものであることを特徴とする請求項1に記載の方法。
- 第1の量の抗体・光増感剤複合体(APC)を患者の体内に注入する手順、
該患者に放射線を当てることにより、該患者の尿中に排出されるリガンドを前記第1の量のAPCから放出させる手順、
液体クロマトグラフィ質量分析により前記リガンドの存在を検出する手順、
前記液体クロマトグラフィ質量分析の分析結果に基づいて前記患者の尿中に存在する前記リガンドの量を測定及び定量化する手順、
前記第1の量のAPCのうち前記患者の体内に残存する分量を求めるために前記患者の尿中に存在する前記リガンドを測定し、定量化された量に基づいて前記近赤外光免疫療法による治療法の有効性を判定する手順、
前記第1の量のAPCのうち前記患者の体内に残存する分量に基づいて決定された第2の量のAPCを前記患者の体内に注入する手順、及び、
該患者に放射線を当てることにより、該患者の尿中に排出されるリガンドを前記第2の量のAPCから放出させる手順
を備えることを特徴とする近赤外光免疫療法による治療法。 - 前記APCの光増感剤が、親水基に結合した疎水性色素骨格を含む両親媒性分子であることを特徴とする請求項12に記載の治療法。
- 前記APCの光増感剤が疎水性色素を含むことを特徴とする請求項12に記載の治療法。
- 前記患者に当てられる放射線が近赤外光であることを特徴とする請求項12に記載の治療法。
- 前記液体クロマトグラフィ質量分析が、三連四重極質量分析装置、プローブエレクトロスプレイイオン化質量分析装置(PESI−MS)、DART(Direct Analysis in Real Time)質量分析装置(DART−MS)又は大気圧固体試料分析プローブ質量分析装置(ASAP−MS)を用いるものであることを特徴とする請求項12に記載の治療法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023030862A JP2023088912A (ja) | 2018-06-21 | 2023-03-01 | 近赤外光免疫療法による治療法を試験するための方法及び装置 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688031P | 2018-06-21 | 2018-06-21 | |
US62/688,031 | 2018-06-21 | ||
PCT/US2019/038097 WO2019246322A1 (en) | 2018-06-21 | 2019-06-20 | Method and apparatus for testing near infrared-photoimmunotherapy treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023030862A Division JP2023088912A (ja) | 2018-06-21 | 2023-03-01 | 近赤外光免疫療法による治療法を試験するための方法及び装置 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021530558A true JP2021530558A (ja) | 2021-11-11 |
Family
ID=68982657
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520095A Pending JP2021530558A (ja) | 2018-06-21 | 2019-06-20 | 近赤外光免疫療法による治療法を試験するための方法 |
JP2023030862A Pending JP2023088912A (ja) | 2018-06-21 | 2023-03-01 | 近赤外光免疫療法による治療法を試験するための方法及び装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023030862A Pending JP2023088912A (ja) | 2018-06-21 | 2023-03-01 | 近赤外光免疫療法による治療法を試験するための方法及び装置 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210263054A1 (ja) |
JP (2) | JP2021530558A (ja) |
WO (1) | WO2019246322A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022107573A1 (ja) * | 2020-11-17 | 2022-05-27 | 国立大学法人東海国立大学機構 | 腫瘍微小環境をターゲットとする光免疫療法に用いる医薬組成物、治療効果確認のためのマーカー、及び検査方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537972A (ja) * | 2003-06-03 | 2007-12-27 | エフ.ホフマン−ラ ロシュ アーゲー | ブプレノルフィンおよびその代謝産物に特異的なモノクローナル抗体 |
JP2017524002A (ja) * | 2014-08-08 | 2017-08-24 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | インビトロおよびインビボにおける標的の光制御除去 |
WO2019172110A1 (ja) * | 2018-03-09 | 2019-09-12 | 学校法人慈恵大学 | 血管を標的とする抗体と光増感剤とのコンジュゲート |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524239B2 (en) * | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
-
2019
- 2019-06-20 WO PCT/US2019/038097 patent/WO2019246322A1/en active Application Filing
- 2019-06-20 US US17/253,671 patent/US20210263054A1/en active Pending
- 2019-06-20 JP JP2021520095A patent/JP2021530558A/ja active Pending
-
2023
- 2023-03-01 JP JP2023030862A patent/JP2023088912A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537972A (ja) * | 2003-06-03 | 2007-12-27 | エフ.ホフマン−ラ ロシュ アーゲー | ブプレノルフィンおよびその代謝産物に特異的なモノクローナル抗体 |
JP2017524002A (ja) * | 2014-08-08 | 2017-08-24 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | インビトロおよびインビボにおける標的の光制御除去 |
WO2019172110A1 (ja) * | 2018-03-09 | 2019-09-12 | 学校法人慈恵大学 | 血管を標的とする抗体と光増感剤とのコンジュゲート |
Non-Patent Citations (4)
Title |
---|
SATO KAZUHIDE: "Elucidation of the Mechanism of Near-Infrared Light-Induced Cell Death and Method Establishment for", READOUT, JPN6022010401, 19 October 2021 (2021-10-19), pages 23 - 28, ISSN: 0004732283 * |
W. G. STILLWELL: "Urinary Excretion of Unmetabolized and Phase II Conjugates of 2-Amino-1-methyl-6-phenylimidazo[4,5-b", CANCER RESEARCH, vol. 57, JPN6022010404, 15 August 1998 (1998-08-15), pages 3457 - 3464, ISSN: 0004732282 * |
中村秀文: "小児麻酔の新たな視点−成長と発達を視野に 薬物動態と薬力学", 日臨麻会誌, vol. 29, no. 7, JPN6022010397, November 2009 (2009-11-01), pages 789 - 796, ISSN: 0004732285 * |
小林久隆: "がんの近赤外光線免疫療法(光免疫療法)", リンパ学, vol. 44, no. 2, JPN6022010399, 31 December 2021 (2021-12-31), pages 58 - 64, ISSN: 0004732284 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023088912A (ja) | 2023-06-27 |
US20210263054A1 (en) | 2021-08-26 |
WO2019246322A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10376600B2 (en) | Early disease detection and therapy | |
Voskuil et al. | Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: a quantitative dose-escalation study | |
Deken et al. | Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session | |
JP4607859B2 (ja) | 蛍光分析物と連動して作動するインビボ蛍光センサ、システム及び関連方法 | |
Ou et al. | Multimodal multiplexed immunoimaging with nanostars to detect multiple immunomarkers and monitor response to immunotherapies | |
US8057418B2 (en) | Devices and methods for extracorporeal ablation of circulating cells | |
US10124186B2 (en) | System for automatically amending energy field characteristics in the application of an energy field to a living organism for treatment of invasive agents | |
Maruoka et al. | Near infrared photoimmunotherapy for cancers: A translational perspective | |
CN107478842B (zh) | 用于肝癌的无创诊断的特异性生物标志物组 | |
Monaco et al. | Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment | |
Xie et al. | Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent | |
CN107206108A (zh) | 术中成像 | |
CN102939538A (zh) | 用于离体检测细胞的诊断方法 | |
JP2023088912A (ja) | 近赤外光免疫療法による治療法を試験するための方法及び装置 | |
Peng et al. | Targeted photodynamic therapy of human head and neck squamous cell carcinoma with anti‐epidermal growth factor receptor antibody cetuximab and photosensitizer ir700dx in the mouse skin‐fold window chamber model | |
Li et al. | Photostimulation of lymphatic clearance of red blood cells from the mouse brain after intraventricular hemorrhage | |
CN106668859B (zh) | 一种对微弱光敏感的光敏药物及其制备方法 | |
Qi et al. | Development of inCVAX, in situ cancer vaccine, and its immune response in mice with hepatocellular cancer | |
Li et al. | Sample-free quantification of blood biomarkers via laser-treated skin | |
WO2012102816A1 (en) | System for correlating energy field characteristics with target particle characteristics in a living organism | |
US10500412B2 (en) | Devices, systems, and methods for inducing dermal blood vessel leakage | |
Conti et al. | Optical imaging detection of microscopic mammary cancer in ErbB‐2 transgenic mice through the DA364 probe binding αvβ3 integrins | |
Prince et al. | Evaluation of fluorescence‐guided surgery agents in a murine model of soft tissue fibrosarcoma | |
US20120190978A1 (en) | System for correlating energy field characteristics with target particle characteristics in the application of the energy field to a living organism for detection of invasive agents | |
RU2638446C1 (ru) | Способ направленного разрушения раковых клеток |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210218 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220812 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221101 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230301 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20230314 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240321 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240418 |